BURST2DNCT05041491
Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes
StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion (estimated)
At risk: Primary completion moved 7 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 15, 2026 to Dec 15, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 25 words
- Enrollment closed, study ongoing
- Study completion pushed from Nov 30, 2026 to Dec 30, 2026
- Secondary endpoints: details revised at 12 of 20 entries
- Site details revised
- Notable Eligibility criteria expanded, about 43 words
- Primary completion date: Dec 2025 to May 15, 2026
- Study completion date: Nov 2026 to Nov 30, 2026
- Notable Primary completion date: Dec 31, 2024 to Dec 2025
- Study completion date: Oct 15, 2025 to Nov 2026
- Notable Eligibility criteria expanded, about 10 words
- Secondary endpoints: details revised at 5 of 20 entries
- Notable Eligibility criteria shortened, about 3 wordsv5
Show 3 earlier versionsHide 3 earlier versions
- Notable Phase: Not applicable to Early Phase 1
- Primary completion date: Aug 2024 to Dec 31, 2024
- Study completion date: Feb 2025 to Oct 15, 2025
- Start date: Dec 6, 2021 to Nov 30, 2021
- Notable Start date: Oct 25, 2021 to Dec 6, 2021
- Eligibility criteria revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 2021 to Oct 25, 2021
- Secondary endpoints revised (20)
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Glycemia
Timeframe: Glucose concentration in mg/dl, measured at fasting, during a 2 hour OGTT and after
Secondary (20)
Insulinemia
Mean interstitial glucose concentration
Daily glycemia variability
Fasting A1c concentration
Fasting fructosamine concentration
Show 15 moreShow less
12-hour exogenous glucose oxidation
12-hour endogenous glucose oxidation
12 hour CO2 production
12 hour O2 production
12 Urine excretion
Glucose kinetics
Fasting and postprandial glucose
Fasting and postprandial insulin
Fasting and postprandial C-Peptide
Fasting and postprandial glucagon
Fasting and postprandial catecholamines
Skeletal muscle content of protein kinase B (Akt) (Aktser473/total)
Skeletal muscle content of ACC (ACCS79/ total)
Skeletal muscle content of TBC1D4 (AS160/ total)
Skeletal muscle content of COX4
Arms and interventions
BREAK InterventionExperimental
Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.
ONE InterventionActive comparator
Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.
Behavioral: BREAK, ONE
Sites
1 site in 1 country
- University of Colorado Anschutz Medical CampusAurora, Colorado, United States